Moderna, Inc. (FRA:0QF)
Market Cap | 8.94B |
Revenue (ttm) | 2.94B |
Net Income (ttm) | -3.11B |
Shares Out | n/a |
EPS (ttm) | -8.07 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 421 |
Average Volume | 14,509 |
Open | 22.70 |
Previous Close | 23.23 |
Day's Range | 22.51 - 23.30 |
52-Week Range | 20.18 - 155.50 |
Beta | n/a |
RSI | 44.69 |
Earnings Date | May 1, 2025 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews

Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:Bernstein's 41st Annual Strategic Decisions...

Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decision...
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.

Moderna's combo Covid and flu mRNA shot outperforms current vaccines in large trial
Moderna’s combined Covid and flu shot outperformed the existing standalone vaccines for both viruses, according to the results of a phase 3 clinical trial published Wednesday in the Journal of the Ame...
SA analyst downgrades: AAPL, SMCI, MRNA, TRIP, IIPR, STLA, TWST

Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell
Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about MRNA stock here.

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna Inc. (NASDAQ: MRNA) reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12) , down from an EPS loss of $(3.07) a year ago. The COVID-19 vaccine maker report...

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026
Moderna Inc. MRNA reported on Thursday a first-quarter EPS loss of $(2.52), missing the consensus of $(3.12), down from an EPS loss of $(3.07) a year ago.
Moderna outlines $1.4B-$1.7B cost reductions by 2027 while advancing oncology pipeline
Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ETCompany ParticipantsLavina Talukdar - Senior Vice President, Investor...
Moderna Stock Slips After Earnings Report. Guidance Was a Silving Lining.
Moderna, Inc. 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by Moderna, Inc.
Moderna to deepen cost cuts amid declining Covid vaccine demand
Moderna GAAP EPS of -$2.52 beats by $0.66, revenue of $100M misses by $15.32M
Moderna Posts Loss, Citing Seasonality of Respiratory Business

Moderna beats Wall Street estimates for first-quarter profit and sales
Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine...
Moderna Misses Sales Forecasts, But Maintains Full-Year Outlook
Moderna stock could take a hit Thursday after the biotech company reported light sales of its Covid vaccine and RSV vaccine.

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52)Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of ...

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of...

Preview: Moderna's Earnings
Moderna (NASDAQ: MRNA) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Moderna to report an ea...
Moderna Q1 Earnings Ahead: Analysts expect loss amid increased regulatory scrutiny
Behind the Scenes of Moderna's Latest Options Trends
Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna . Looking at options history for Moderna (NASDAQ: MRNA) we detected 13 trades. If we consider the specifics of ea...
More Downside For Moderna Before The Breakthrough

33 Stocks That Could Rally 50% or More This Year
Analysts say these S&P 500 stocks have at least 50% price upside over the next year or so.